241 results
Page 4 of 13
8-K
EX-99.1
lnwv2qzqgv ej9z7
13 May 21
Humanigen Reports First Quarter 2021 Financial Results
4:06pm
8-K
h7w32 slc
20 Apr 21
Humanigen Reports Positive Data with Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
5:28pm
8-K
EX-99.1
qpvdoegiv5plejpph
20 Apr 21
Humanigen Reports Positive Data with Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
5:28pm
8-K
EX-1.1
ahf00 8e215n
2 Apr 21
Other Events
5:00pm
424B5
1at9srmh 1om
1 Apr 21
Prospectus supplement for primary offering
6:02am
424B5
v6drbw5 rm
29 Mar 21
Prospectus supplement for primary offering
4:39pm
8-K
EX-99.2
5tmdc0ivlrmk472wzoj
29 Mar 21
Regulation FD Disclosure
9:18am
8-K
EX-99.1
hy9g29fk9d ob
29 Mar 21
Regulation FD Disclosure
9:18am
8-K
n34v2lu9yz5
29 Mar 21
Regulation FD Disclosure
9:18am
8-K
EX-99.1
45k7a3gr
29 Jan 21
Humanigen Completes Enrollment in Phase 3 Study of Lenzilumab in Hospitalized Patients with COVID-19
7:30am
8-K
ip98y6n7 jvrx9oux1a1
22 Jan 21
Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19
10:41am
8-K
EX-99.1
1err5rt
22 Jan 21
Humanigen Announces the Addition of BARDA and Expansion of CRADA with the U.S. Government to Develop Lenzilumab for COVID-19
10:41am
8-K
EX-99.1
bjd yehbcj6ep
14 Jan 21
Humanigen and EVERSANA Announce Partnership to Support the Launch and Commercialization of Lenzilumab for the Treatment of COVID-19
4:30pm
424B5
k3gwyf0
31 Dec 20
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
vrpwk9
31 Dec 20
Other Events
4:37pm